fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Tranexamic acid

All products: not a benefit

Gd-Tranexamic Acid · DIN 02409097 · 500 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Gd-Tranexamic Acid · DIN 02409097 Manufacturer: Genmed, A Division of Pfizer Canada Inc.; listing date 2015-07-29 Health Canada: Marketed since 2014-03-07 · brand GD-TRANEXAMIC ACID · ATC B02AA02 TRANEXAMIC ACID · form Tablet · route Oral · ingredients TRANEXAMIC ACID 500 MG · company Genmed a division of pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Gd-Tranexamic Acid: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8071). What the ministry pays, not the patient.

Ministry pays: $0.8071 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02409097)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02409097). DIN 02409097: Gd-Tranexamic Acid Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 201216003; group id 265; item number 0534; lccId None; manufacturer id GEM Source form: Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.8071; ministry $0.8071 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02409097 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89382
Interchangeable products
Cyklokapron · DIN 02064405 · not recorded Mar-Tranexamic Acid · DIN 02496232 · $0.8071 Tranexamic Acid · DIN 02519194 · $0.8071 Tranexamic Acid Tablets · DIN 02401231 · $0.8071
Shortage status: resolved shortage (ended August 13, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02409097
Shortage record checked October 6, 2026
Other drugs in the same formulary class (20:12:16 Hemostatics) and how they are covered
No products matched this class search: “20:12:16”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 20:12:04 Direct Factor Xa Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CYKLOKAPRON® (tranexamic acid) is indicated for:  Hereditary angioneurotic oedema.  Increased local fibrinolysis when the diagnosis is indicative of hyperfibrinolysis, as with conization of the cervix, dental extraction in patients with coagulopathies (in conjunction with antihaemophilic factor) epistaxis, hyphaema, and menorrhagia (hypermenorrhea). 1.1 Pediatrics Based on the data submitted and reviewed by Health Canada, the safety and efficacy of CYKLOKAPRON in pediatric patients has been established for use in hereditary angioneurotic oedema and increased local fibrinolysis when the diagnosis is indicative of hyperfibrinolysis. Specific data is available for surgical patients undergoing cardiac and orthopedic surgeries. Therefore, Health Canada has authorized CYKLOKAPRON in these indications for pediatric use. For menorrhagia (hypermenorrhea), limited data are available to Health Canada. Clinical experience with CYKLOKAPRON in menorrhagic (hypermenorrhea) children under 18 years of age is not available. Therefore, Health Canada has not authorized CYKLOKAPRON for this indication for pediatric use. 1.2 Geriatrics Clinical studies … https://pdf.hres.ca/dpd_pm/00063720.PDF PM date: DEC 05, 1995 Source product: CYKLOKAPRON 500 MG; DIN 02064405; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Gd-Tranexamic Acid: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026